Business Wire

BACARDI

12.9.2022 13:01:51 CEST | Business Wire | Press release

Share
Bacardi Announces New Leadership for Its Global Travel Retail Business

Bacardi announces a change at the top of its global travel retail business (GTR), effective January 2023. The current Managing Director, Vinay Golikeri, moves out of global travel retail to take on the role of Managing Director, India, and Neighboring Countries, handing over the reins to Leila Stansfield. Leila is an experienced global travel retail veteran, having previously held roles as GTR Finance Director and GTR Marketing Director. She will be the first female lead for the division. She is currently On-Trade Sales Director, Bacardi UK & Ireland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005141/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Leila Stansfield to lead Bacardi global travel retail business (GTR), effective January 2023. (Photo: Business Wire)

Vijay Subramaniam, Regional President AMEA & GTR, Bacardi comments on the change, “Vinay has played a pivotal role in leading and developing our global travel retail business. The last few years have been particularly difficult for this channel, and Vinay has successfully navigated the challenges of the pandemic. He has spearheaded our ambitions as a front-runner in the omnichannel revolution sweeping travel retail by partnering with retail customers, introducing significant innovation in shopper experience and our brand portfolio. I would like to thank Vinay for his unwavering drive and positive leadership and to wish him every success in his new role.

“Meanwhile, we are delighted to welcome Leila Stansfield back to GTR. She is a driving force in our senior leadership team and brings valuable commercial acumen from across several aspects of our business. This is a time of transformational opportunity for global travel retail and Bacardi is deeply committed for the long term. With a passion for people – our customers, consumers and for unlocking potential in her team - Leila will be a tremendous leader to move GTR into the new omnichannel era, maximizing the unrivaled dynamics in terms of strategic brand-building and commercial opportunity as well as driving our ESG goals – a key objective in our strategic ambitions for global travel retail.”

Commenting on his time in Bacardi GTR, Vinay Golikeri said, “It’s been such a privilege to lead the Bacardi global travel retail business, and I would especially like to call out the most magnificent team of talented people I’ve worked with and to thank them for their fearless commitment and passion. These individuals have delivered phenomenal work in the toughest of times, enabling us to reinvent our business in global travel retail and to emerge stronger with new possibilities, notably in forging omnichannel solutions that are the bedrock of the new era in this remarkable market.”

Looking ahead to her new role, Leila Stansfield adds, “I am very excited to be returning to global travel retail in January 2023, especially at a time when the market looks set to move towards full recovery. I look forward to reconnecting with our retail partners and stakeholders to accelerate and deliver mutually beneficial strategies for growth.”

NOTES TO EDITORS

About BACARDI GLOBAL TRAVEL RETAIL

The Bacardi Global Travel Retail Division is a stand-alone business unit of Bacardi Limited. Through Bacardi’s portfolio of premium and super-premium brands, including BACARDÍ® rum, GREY GOOSE® vodka, DEWAR’S® blended Scotch whisky, BOMBAY SAPPHIRE® gin, PATRÓN® tequila, MARTINI® vermouth and sparkling wine, SAINT GERMAIN® liqueur, BARON OTARD® cognac, BÉNÉDICTINE® liqueur, and 42BELOW® vodka, the Bacardi Global Travel Retail Division creates unique and innovative experiences for travelers.

The brands noted above are part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Drink Responsibly

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005141/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye